Do analysts prefer ORMP or SLDB?

Solid Biosciences has a consensus target price of $18.69, suggesting a potential upside of 221.17%. Given Solid Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Solid Biosciences is more favorable than Oramed Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oramed Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Solid Biosciences 1 Sell rating(s) 0 Hold rating(s) 12 Buy rating(s) 0 Strong Buy rating(s) 2.85

Is ORMP or SLDB more profitable?

Oramed Pharmaceuticals' return on equity of -5.17% beat Solid Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Oramed Pharmaceuticals N/A -5.17% -4.54% Solid Biosciences N/A -71.35% -60.58%

Does the media refer more to ORMP or SLDB?

In the previous week, Solid Biosciences had 2 more articles in the media than Oramed Pharmaceuticals. MarketBeat recorded 4 mentions for Solid Biosciences and 2 mentions for Oramed Pharmaceuticals. Solid Biosciences' average media sentiment score of 1.01 beat Oramed Pharmaceuticals' score of 0.89 indicating that Solid Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oramed Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Solid Biosciences 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate ORMP or WVE?

WAVE Life Sciences has a consensus price target of $21.65, indicating a potential upside of 589.40%. Given WAVE Life Sciences' stronger consensus rating and higher possible upside, analysts plainly believe WAVE Life Sciences is more favorable than Oramed Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oramed Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 WAVE Life Sciences 1 Sell rating(s) 2 Hold rating(s) 15 Buy rating(s) 0 Strong Buy rating(s) 2.78

Does the media refer more to ORMP or WVE?

In the previous week, WAVE Life Sciences had 3 more articles in the media than Oramed Pharmaceuticals. MarketBeat recorded 5 mentions for WAVE Life Sciences and 2 mentions for Oramed Pharmaceuticals. Oramed Pharmaceuticals' average media sentiment score of 0.89 beat WAVE Life Sciences' score of -0.01 indicating that Oramed Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oramed Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive WAVE Life Sciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Do analysts prefer IMMX or ORMP?

Immix Biopharma currently has a consensus price target of $24.14, suggesting a potential upside of 177.82%. Given Immix Biopharma's stronger consensus rating and higher probable upside, research analysts clearly believe Immix Biopharma is more favorable than Oramed Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Immix Biopharma 1 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.78 Oramed Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is IMMX or ORMP more profitable?

Oramed Pharmaceuticals' return on equity of -5.17% beat Immix Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Immix Biopharma N/A -38.44% -34.72% Oramed Pharmaceuticals N/A -5.17% -4.54%

Does the media prefer IMMX or ORMP?

In the previous week, Immix Biopharma and Immix Biopharma both had 2 articles in the media. Immix Biopharma's average media sentiment score of 1.79 beat Oramed Pharmaceuticals' score of 0.89 indicating that Immix Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immix Biopharma 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Oramed Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend ORMP or VSTM?

Verastem has a consensus price target of $13.83, suggesting a potential upside of 85.68%. Given Verastem's stronger consensus rating and higher possible upside, analysts plainly believe Verastem is more favorable than Oramed Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oramed Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Verastem 1 Sell rating(s) 1 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.75

Does the media refer more to ORMP or VSTM?

In the previous week, Verastem had 1 more articles in the media than Oramed Pharmaceuticals. MarketBeat recorded 3 mentions for Verastem and 2 mentions for Oramed Pharmaceuticals. Oramed Pharmaceuticals' average media sentiment score of 0.89 beat Verastem's score of 0.69 indicating that Oramed Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oramed Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Verastem 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend ORMP or OLMA?

Olema Pharmaceuticals has a consensus target price of $40.60, indicating a potential upside of 478.35%. Given Olema Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Olema Pharmaceuticals is more favorable than Oramed Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oramed Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Olema Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 2.77

Is ORMP or OLMA more profitable?

Oramed Pharmaceuticals' return on equity of -5.17% beat Olema Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Oramed Pharmaceuticals N/A -5.17% -4.54% Olema Pharmaceuticals N/A -48.26% -43.04%

Does the media favor ORMP or OLMA?

In the previous week, Oramed Pharmaceuticals and Oramed Pharmaceuticals both had 2 articles in the media. Olema Pharmaceuticals' average media sentiment score of 0.91 beat Oramed Pharmaceuticals' score of 0.89 indicating that Olema Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oramed Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Olema Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Oramed Pharmaceuticals (ORMP) Competitors

$4.20 -0.08 (-1.76%)

As of 09:55 AM Eastern

Compare

ORMP vs. SLDB, WVE, IMMX, VSTM, and OLMA

Should you buy Oramed Pharmaceuticals stock or one of its competitors? Oramed Pharmaceuticals's main competitors and comparable companies include Solid Biosciences (SLDB), WAVE Life Sciences (WVE), Immix Biopharma (IMMX), Verastem (VSTM), and Olema Pharmaceuticals (OLMA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Oramed Pharmaceuticals compare to Solid Biosciences?

Oramed Pharmaceuticals (NASDAQ:ORMP) and Solid Biosciences (NASDAQ:SLDB) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, media sentiment, dividends, analyst recommendations, valuation, risk and profitability.

Solid Biosciences has a consensus target price of $18.69, suggesting a potential upside of 221.17%. Given Solid Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Solid Biosciences is more favorable than Oramed Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oramed Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Solid Biosciences	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85

Oramed Pharmaceuticals' return on equity of -5.17% beat Solid Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oramed Pharmaceuticals	N/A	-5.17%	-4.54%
Solid Biosciences	N/A	-71.35%	-60.58%

In the previous week, Solid Biosciences had 2 more articles in the media than Oramed Pharmaceuticals. MarketBeat recorded 4 mentions for Solid Biosciences and 2 mentions for Oramed Pharmaceuticals. Solid Biosciences' average media sentiment score of 1.01 beat Oramed Pharmaceuticals' score of 0.89 indicating that Solid Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oramed Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Solid Biosciences	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Oramed Pharmaceuticals has higher revenue and earnings than Solid Biosciences. Solid Biosciences is trading at a lower price-to-earnings ratio than Oramed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oramed Pharmaceuticals	$2M	86.74	$64.05M	$4.12	1.01
Solid Biosciences	N/A	N/A	-$174.32M	-$1.91	N/A

12.7% of Oramed Pharmaceuticals shares are owned by institutional investors. Comparatively, 81.5% of Solid Biosciences shares are owned by institutional investors. 20.8% of Oramed Pharmaceuticals shares are owned by insiders. Comparatively, 2.7% of Solid Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Oramed Pharmaceuticals has a beta of 1.29, indicating that its stock price is 29% more volatile than the broader market. Comparatively, Solid Biosciences has a beta of 2.47, indicating that its stock price is 147% more volatile than the broader market.

Summary

Solid Biosciences beats Oramed Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

How does Oramed Pharmaceuticals compare to WAVE Life Sciences?

Oramed Pharmaceuticals (NASDAQ:ORMP) and WAVE Life Sciences (NASDAQ:WVE) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, risk, profitability, analyst recommendations, institutional ownership and media sentiment.

Oramed Pharmaceuticals has a net margin of 0.00% compared to WAVE Life Sciences' net margin of -309.73%. Oramed Pharmaceuticals' return on equity of -5.17% beat WAVE Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oramed Pharmaceuticals	N/A	-5.17%	-4.54%
WAVE Life Sciences	-309.73%	-50.36%	-40.06%

WAVE Life Sciences has a consensus price target of $21.65, indicating a potential upside of 589.40%. Given WAVE Life Sciences' stronger consensus rating and higher possible upside, analysts plainly believe WAVE Life Sciences is more favorable than Oramed Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oramed Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
WAVE Life Sciences	1 Sell rating(s)	2 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.78

Oramed Pharmaceuticals has higher earnings, but lower revenue than WAVE Life Sciences. WAVE Life Sciences is trading at a lower price-to-earnings ratio than Oramed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oramed Pharmaceuticals	$2M	86.74	$64.05M	$4.12	1.01
WAVE Life Sciences	$42.73M	14.48	-$204.38M	-$1.09	N/A

12.7% of Oramed Pharmaceuticals shares are owned by institutional investors. Comparatively, 89.7% of WAVE Life Sciences shares are owned by institutional investors. 20.8% of Oramed Pharmaceuticals shares are owned by company insiders. Comparatively, 24.3% of WAVE Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Oramed Pharmaceuticals has a beta of 1.29, indicating that its share price is 29% more volatile than the broader market. Comparatively, WAVE Life Sciences has a beta of -1.43, indicating that its share price is 243% less volatile than the broader market.

In the previous week, WAVE Life Sciences had 3 more articles in the media than Oramed Pharmaceuticals. MarketBeat recorded 5 mentions for WAVE Life Sciences and 2 mentions for Oramed Pharmaceuticals. Oramed Pharmaceuticals' average media sentiment score of 0.89 beat WAVE Life Sciences' score of -0.01 indicating that Oramed Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oramed Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
WAVE Life Sciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

Oramed Pharmaceuticals beats WAVE Life Sciences on 8 of the 15 factors compared between the two stocks.

How does Oramed Pharmaceuticals compare to Immix Biopharma?

Immix Biopharma (NASDAQ:IMMX) and Oramed Pharmaceuticals (NASDAQ:ORMP) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, risk, profitability, dividends, earnings and media sentiment.

Immix Biopharma currently has a consensus price target of $24.14, suggesting a potential upside of 177.82%. Given Immix Biopharma's stronger consensus rating and higher probable upside, research analysts clearly believe Immix Biopharma is more favorable than Oramed Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immix Biopharma	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.78
Oramed Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Immix Biopharma has a beta of 0.24, indicating that its stock price is 76% less volatile than the broader market. Comparatively, Oramed Pharmaceuticals has a beta of 1.29, indicating that its stock price is 29% more volatile than the broader market.

11.3% of Immix Biopharma shares are owned by institutional investors. Comparatively, 12.7% of Oramed Pharmaceuticals shares are owned by institutional investors. 30.3% of Immix Biopharma shares are owned by insiders. Comparatively, 20.8% of Oramed Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Immix Biopharma and Immix Biopharma both had 2 articles in the media. Immix Biopharma's average media sentiment score of 1.79 beat Oramed Pharmaceuticals' score of 0.89 indicating that Immix Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immix Biopharma	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Oramed Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Oramed Pharmaceuticals' return on equity of -5.17% beat Immix Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immix Biopharma	N/A	-38.44%	-34.72%
Oramed Pharmaceuticals	N/A	-5.17%	-4.54%

Oramed Pharmaceuticals has higher revenue and earnings than Immix Biopharma. Immix Biopharma is trading at a lower price-to-earnings ratio than Oramed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immix Biopharma	N/A	N/A	-$29.44M	-$0.88	N/A
Oramed Pharmaceuticals	$2M	86.74	$64.05M	$4.12	1.01

Summary

Oramed Pharmaceuticals beats Immix Biopharma on 8 of the 13 factors compared between the two stocks.

How does Oramed Pharmaceuticals compare to Verastem?

Oramed Pharmaceuticals (NASDAQ:ORMP) and Verastem (NASDAQ:VSTM) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

12.7% of Oramed Pharmaceuticals shares are held by institutional investors. Comparatively, 88.4% of Verastem shares are held by institutional investors. 20.8% of Oramed Pharmaceuticals shares are held by company insiders. Comparatively, 1.9% of Verastem shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Oramed Pharmaceuticals has higher earnings, but lower revenue than Verastem. Verastem is trading at a lower price-to-earnings ratio than Oramed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oramed Pharmaceuticals	$2M	86.74	$64.05M	$4.12	1.01
Verastem	$30.91M	21.83	-$209.47M	-$2.66	N/A

In the previous week, Verastem had 1 more articles in the media than Oramed Pharmaceuticals. MarketBeat recorded 3 mentions for Verastem and 2 mentions for Oramed Pharmaceuticals. Oramed Pharmaceuticals' average media sentiment score of 0.89 beat Verastem's score of 0.69 indicating that Oramed Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oramed Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Verastem	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Oramed Pharmaceuticals has a net margin of 0.00% compared to Verastem's net margin of -231.59%. Oramed Pharmaceuticals' return on equity of -5.17% beat Verastem's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oramed Pharmaceuticals	N/A	-5.17%	-4.54%
Verastem	-231.59%	-467.49%	-94.54%

Verastem has a consensus price target of $13.83, suggesting a potential upside of 85.68%. Given Verastem's stronger consensus rating and higher possible upside, analysts plainly believe Verastem is more favorable than Oramed Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oramed Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Verastem	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

Oramed Pharmaceuticals has a beta of 1.29, meaning that its share price is 29% more volatile than the broader market. Comparatively, Verastem has a beta of 0.39, meaning that its share price is 61% less volatile than the broader market.

Summary

Oramed Pharmaceuticals beats Verastem on 10 of the 16 factors compared between the two stocks.

How does Oramed Pharmaceuticals compare to Olema Pharmaceuticals?

Oramed Pharmaceuticals (NASDAQ:ORMP) and Olema Pharmaceuticals (NASDAQ:OLMA) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, earnings, analyst recommendations, institutional ownership, risk and valuation.

Olema Pharmaceuticals has a consensus target price of $40.60, indicating a potential upside of 478.35%. Given Olema Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Olema Pharmaceuticals is more favorable than Oramed Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oramed Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Olema Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.77

Oramed Pharmaceuticals has higher revenue and earnings than Olema Pharmaceuticals. Olema Pharmaceuticals is trading at a lower price-to-earnings ratio than Oramed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oramed Pharmaceuticals	$2M	86.74	$64.05M	$4.12	1.01
Olema Pharmaceuticals	N/A	N/A	-$162.45M	-$2.12	N/A

In the previous week, Oramed Pharmaceuticals and Oramed Pharmaceuticals both had 2 articles in the media. Olema Pharmaceuticals' average media sentiment score of 0.91 beat Oramed Pharmaceuticals' score of 0.89 indicating that Olema Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oramed Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Olema Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

12.7% of Oramed Pharmaceuticals shares are held by institutional investors. Comparatively, 91.8% of Olema Pharmaceuticals shares are held by institutional investors. 20.8% of Oramed Pharmaceuticals shares are held by company insiders. Comparatively, 12.6% of Olema Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Oramed Pharmaceuticals has a beta of 1.29, suggesting that its share price is 29% more volatile than the broader market. Comparatively, Olema Pharmaceuticals has a beta of 2, suggesting that its share price is 100% more volatile than the broader market.

Oramed Pharmaceuticals' return on equity of -5.17% beat Olema Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oramed Pharmaceuticals	N/A	-5.17%	-4.54%
Olema Pharmaceuticals	N/A	-48.26%	-43.04%

Summary

Oramed Pharmaceuticals beats Olema Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

Get Oramed Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ORMP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ORMP vs. The Competition

Export

Metric	Oramed Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$171.93M	$3.93B	$7.26B	$13.21B
Dividend Yield	5.85%	3.65%	2.52%	22.89%
P/E Ratio	1.00	11.31	206.66	19.94
Price / Sales	86.01	1,148.46	562.21	81.34
Price / Cash	47.07	118.50	77.16	53.04
Price / Book	0.82	17.08	10.75	6.03
Net Income	$64.05M	-$22.69M	$3.50B	$380.34M
7 Day Performance	-5.38%	-4.43%	-2.91%	-2.34%
1 Month Performance	-11.46%	-12.48%	-7.38%	-5.31%
1 Year Performance	75.21%	7.60%	2.96%	-2.94%

Oramed Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ORMP Oramed Pharmaceuticals	2.0402 of 5 stars	$4.20 -1.8%	N/A	+73.0%	$174.51M	$2M	1.02	13	Gap Up
SLDB Solid Biosciences	3.1427 of 5 stars	$6.92 -2.0%	$18.69 +170.1%	-3.2%	$757.01M	N/A	N/A	121	Positive News
WVE WAVE Life Sciences	2.4954 of 5 stars	$3.52 -6.1%	$21.65 +515.0%	-59.7%	$738.93M	$42.73M	N/A	317
IMMX Immix Biopharma	3.2527 of 5 stars	$9.64 -4.8%	$24.14 +150.4%	+247.6%	$724.69M	N/A	N/A	21	Positive News
VSTM Verastem	3.6243 of 5 stars	$7.75 -3.1%	$13.83 +78.5%	-19.8%	$724.50M	$87.53M	N/A	102	Trending News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ORMP) was last updated on 10/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Oramed Pharmaceuticals (ORMP) Competitors

ORMP vs. SLDB, WVE, IMMX, VSTM, and OLMA

How does Oramed Pharmaceuticals compare to Solid Biosciences?

Summary

How does Oramed Pharmaceuticals compare to WAVE Life Sciences?

Summary

How does Oramed Pharmaceuticals compare to Immix Biopharma?

Summary

How does Oramed Pharmaceuticals compare to Verastem?

Summary

How does Oramed Pharmaceuticals compare to Olema Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ORMP vs. The Competition

Oramed Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Oramed Pharmaceuticals (ORMP) Competitors

ORMP vs. SLDB, WVE, IMMX, VSTM, and OLMA

How does Oramed Pharmaceuticals compare to Solid Biosciences?

Do analysts prefer ORMP or SLDB?

Is ORMP or SLDB more profitable?

Does the media refer more to ORMP or SLDB?

Which has stronger earnings & valuation, ORMP or SLDB?

Do institutionals and insiders have more ownership in ORMP or SLDB?

Which has more risk & volatility, ORMP or SLDB?

Summary

How does Oramed Pharmaceuticals compare to WAVE Life Sciences?

Is ORMP or WVE more profitable?

Do analysts rate ORMP or WVE?

Which has preferable earnings and valuation, ORMP or WVE?

Do institutionals and insiders believe in ORMP or WVE?

Which has more risk and volatility, ORMP or WVE?

Does the media refer more to ORMP or WVE?

Summary

How does Oramed Pharmaceuticals compare to Immix Biopharma?

Do analysts prefer IMMX or ORMP?

Which has more volatility and risk, IMMX or ORMP?

Do institutionals and insiders hold more shares of IMMX or ORMP?

Does the media prefer IMMX or ORMP?

Is IMMX or ORMP more profitable?

Which has preferable valuation & earnings, IMMX or ORMP?

Summary

How does Oramed Pharmaceuticals compare to Verastem?

Do insiders & institutionals hold more shares of ORMP or VSTM?

Which has higher valuation & earnings, ORMP or VSTM?

Does the media refer more to ORMP or VSTM?

Is ORMP or VSTM more profitable?

Do analysts recommend ORMP or VSTM?

Which has more risk & volatility, ORMP or VSTM?

Summary

How does Oramed Pharmaceuticals compare to Olema Pharmaceuticals?

Do analysts recommend ORMP or OLMA?

Which has preferable earnings and valuation, ORMP or OLMA?

Does the media favor ORMP or OLMA?

Do insiders & institutionals believe in ORMP or OLMA?

Which has more risk & volatility, ORMP or OLMA?

Is ORMP or OLMA more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ORMP vs. The Competition

Oramed Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools